Food Certifiers Pay Up: FDA's 2026 Fee Adjustment
Published Date: 7/30/2025
Notice
Summary
Starting in fiscal year 2026, the FDA is updating the fees for groups that check food safety under the Food Safety Modernization Act. This affects accreditation and certification bodies who want to get or keep their official approval. The new fees help keep food safety checks strong and fair, with changes kicking in soon to keep everyone on track.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
FY2026 Annual Fee for Recognized Bodies
Starting in fiscal year (FY) 2026, the FDA sets the annual fee rate that applies to already recognized accreditation bodies and accredited certification bodies in the FSMA third-party certification program. If you run or manage an accredited body, you will be charged this annual fee to keep your recognition and participation in the program.
Fee for Direct FDA Accreditation Applicants
The FDA announces the fee rate for certification bodies that apply for direct FDA accreditation in fiscal year 2026. If your certification body is seeking direct accreditation from FDA in FY2026, you will be required to pay the stated application fee.
Initial and Renewal Recognition Fees
For fiscal year 2026, the FDA announces the initial and renewal fee rates that accreditation bodies must pay when applying to be recognized in the FSMA third-party certification program. If you plan to apply for new recognition or renew recognition as an accreditation body, you will need to pay these application or renewal fees in FY2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-14414 — Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2026
Starting in fiscal year 2026, the FDA is updating fees for checking food facilities again, handling recall slip-ups, and re-inspecting importers. If you run or import food businesses, expect some changes in costs and timing for these inspections. These updates help keep our food safe and make sure everyone plays by the rules.
Next: 2025-14416 — Biosimilar User Fee Rates for Fiscal Year 2026
The FDA is setting new fees for companies working on biosimilar drugs in fiscal year 2026. If you’re developing or getting approval for these drugs, expect some updated costs starting October 1, 2025. These fees help the FDA keep reviews speedy and safe, so everyone wins!